Charles Schwab Investment Management Inc. Purchases 53,319 Shares of BioNTech SE (NASDAQ:BNTX)

Charles Schwab Investment Management Inc. increased its position in BioNTech SE (NASDAQ:BNTX) by 39.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 187,355 shares of the company’s stock after purchasing an additional 53,319 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.08% of BioNTech worth $21,349,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its position in BioNTech by 4.3% during the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company’s stock valued at $419,000 after acquiring an additional 150 shares in the last quarter. Perigon Wealth Management LLC boosted its position in BioNTech by 3.9% during the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company’s stock valued at $666,000 after acquiring an additional 224 shares in the last quarter. Atomi Financial Group Inc. boosted its position in BioNTech by 6.7% during the 4th quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company’s stock valued at $414,000 after acquiring an additional 229 shares in the last quarter. Jones Financial Companies Lllp boosted its position in BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after acquiring an additional 300 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Wells Fargo & Company assumed coverage on BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price on the stock. Truist Financial started coverage on BioNTech in a research report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Citigroup started coverage on BioNTech in a research report on Thursday, March 13th. They issued a “buy” rating and a $145.00 price objective for the company. BMO Capital Markets raised their price objective on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Stock Performance

Shares of BNTX stock opened at $99.27 on Thursday. The firm has a market capitalization of $23.80 billion, a price-to-earnings ratio of -47.27 and a beta of 0.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The business has a fifty day moving average of $114.09 and a 200 day moving average of $113.44. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business posted $1.90 EPS. As a group, research analysts expect that BioNTech SE will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.